Bellicum Pharmaceuticals, Inc., a clinical stage biopharma company developing novel cellular immunotherapies, has entered into a lease agreement to enable in-house cell therapy manufacturing to supply clinical trials. The additional 27,000 sq.-ft. will be located at the company’s current headquarters adjacent to the Texas Medical Center in Houston.
 
“Bringing manufacturing in-house allows us to build upon our process and assay development expertise and streamline the production of our cell therapy product candidates, under our full control,” said Tom Farrell, Bellicum’s president and chief executive officer. “The planned facility is intended to provide study drug for clinical studies of BPX-501 and to support the development of our expanding pipeline of TCR and CAR-T adoptive cell therapy product candidates.”